Huntington's disease (HD) is a rare, autosomal dominant neurodegenerative disorder characterized by involuntary choreic movements, psychiatric disturbances, and cognitive decline. It affects approximately 1 in 10,000 to 1 in 20,000 Caucasians, with an average age of onset between 30 and 50 years. Juvenile HD, starting before age 20, is less common and often has a longer CAG repeat. The disease is caused by an expanded CAG repeat in the HTT gene on chromosome 4p16.3. Diagnosis is based on clinical symptoms and confirmed by DNA testing. Premanifest diagnosis requires a multidisciplinary approach. HD is associated with a range of non-motor symptoms, including weight loss, sleep disturbances, and autonomic dysfunction. There is no cure, and management focuses on symptom relief to improve quality of life. Treatments include dopamine receptor blockers for chorea, antidepressants, and antipsychotics for psychiatric symptoms. The disease progresses to severe disability, with common causes of death being pneumonia and suicide. HD is a lifelong condition with significant social and psychological impact. Research has focused on understanding the pathophysiology and developing disease-modifying therapies. Prenatal and preimplantation diagnosis are available in some countries. Despite advances, no effective treatment exists, and care is primarily supportive. Future research aims to identify biomarkers and develop targeted therapies. HD remains a challenging condition requiring multidisciplinary care and ongoing research.Huntington's disease (HD) is a rare, autosomal dominant neurodegenerative disorder characterized by involuntary choreic movements, psychiatric disturbances, and cognitive decline. It affects approximately 1 in 10,000 to 1 in 20,000 Caucasians, with an average age of onset between 30 and 50 years. Juvenile HD, starting before age 20, is less common and often has a longer CAG repeat. The disease is caused by an expanded CAG repeat in the HTT gene on chromosome 4p16.3. Diagnosis is based on clinical symptoms and confirmed by DNA testing. Premanifest diagnosis requires a multidisciplinary approach. HD is associated with a range of non-motor symptoms, including weight loss, sleep disturbances, and autonomic dysfunction. There is no cure, and management focuses on symptom relief to improve quality of life. Treatments include dopamine receptor blockers for chorea, antidepressants, and antipsychotics for psychiatric symptoms. The disease progresses to severe disability, with common causes of death being pneumonia and suicide. HD is a lifelong condition with significant social and psychological impact. Research has focused on understanding the pathophysiology and developing disease-modifying therapies. Prenatal and preimplantation diagnosis are available in some countries. Despite advances, no effective treatment exists, and care is primarily supportive. Future research aims to identify biomarkers and develop targeted therapies. HD remains a challenging condition requiring multidisciplinary care and ongoing research.